Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Citigroup's Joanne Wuensch made a flurry of medical device calls on Monday. She trimmed targets on three names while lifting JNJ to a $303 price target from $298, maintaining a Buy. Boston Scientific and GE HealthCare both saw targets cut, to $48 and $71 respectively. Baxter International was also trimmed to $27. The pattern suggests Wuensch is rotating preference toward the pharma giant and away from device makers.
UBS chemicals analyst Joshua Spector cut targets on two names in the same session. Albemarle was reduced to $150 from $175, with the Buy rating intact. Lithium market pressure is clearly weighing on the call. was cut to $305 from $336 and kept at Hold.
Against the trend, UBS lifted Gartner to $208 from $196, keeping Hold. The IT research firm benefits from rising enterprise demand for AI governance tools.
Financials saw quiet optimism. Citigroup raised targets on State Street to $212 and Northern Trust to $186. Both keep Buy and Hold ratings respectively. Record buyback authorisations of $58.2bn in Q2 2026, the largest on record according to ORTEX alt data, support the positive case for capital-return-driven financials.
MSCI saw a consensus target trimmed slightly to $688 from $692.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
